Protective and disease-enhancing immune responses to respiratory syncytial virus
LJ Anderson, CA Heilman - Journal of Infectious Diseases, 1995 - academic.oup.com
Abstract The National Institutes of Health, Centers for Disease Control and Prevention, and
World Health Organization jointly sponsored a workshop on protective and disease …
World Health Organization jointly sponsored a workshop on protective and disease …
Pathogenesis of respiratory syncytial virus vaccine-augmented pathology
SG Barney - Am J Respir Crit Care Med, 1995 - atsjournals.org
Respiratory syncytial virus (RSV) is an important cause of respiratory illness in children and
adults. Development of an effective vaccine against RSV faces three major challenges. First …
adults. Development of an effective vaccine against RSV faces three major challenges. First …
Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection
A Mejias, C Garcia-Maurino, R Rodriguez-Fernandez… - Vaccine, 2017 - Elsevier
Respiratory syncytial virus (RSV) remains a significant cause of morbidity and mortality in
infants and young children, immunocompromised patients and the elderly. Despite the high …
infants and young children, immunocompromised patients and the elderly. Despite the high …
Prevention and treatment of respiratory syncytial virus infection in infants: an update
MP Venkatesh, LE Weisman - Expert review of vaccines, 2006 - Taylor & Francis
Respiratory syncytial virus (RSV) is a serious pathogen causing significant mortality and
morbidity, especially in premature infants and infants with chronic lung disease or significant …
morbidity, especially in premature infants and infants with chronic lung disease or significant …
Vaccination against RSV: is maternal vaccination a good alternative to other approaches?
P Kaaijk, W Luytjes, NY Rots - Human vaccines & …, 2013 - Taylor & Francis
The respiratory syncytial virus (RSV) is the major cause of lower respiratory tract illness (LRI)
in infants worldwide. Also persons with heart/lung disease or an immunodeficiency disorder …
in infants worldwide. Also persons with heart/lung disease or an immunodeficiency disorder …
[HTML][HTML] WHO consultation on respiratory syncytial virus vaccine development report from a World Health Organization meeting held on 23–24 March 2015
K Modjarrad, B Giersing, DC Kaslow, PG Smith… - Vaccine, 2016 - Elsevier
Respiratory syncytial virus (RSV) is a globally prevalent cause of lower respiratory infection
in neonates and infants. Despite its disease burden, a safe and effective RSV vaccine has …
in neonates and infants. Despite its disease burden, a safe and effective RSV vaccine has …
Development of respiratory syncytial virus (RSV) vaccines for infants
HE Gerretsen, CJ Sande - Journal of Infection, 2017 - Elsevier
Summary 2017 will mark the 60 th anniversary since the first isolation of RSV in children. In
spite of concerted efforts over all these years, the goal of developing an effective vaccine …
spite of concerted efforts over all these years, the goal of developing an effective vaccine …
[PDF][PDF] Immunogenicity and protective efficacy of a dual subunit vaccine against respiratory syncytial virus and influenza virus
MH Park, J Chang - Immune network, 2012 - synapse.koreamed.org
Since the respiratory syncytial virus (RSV) was initially isolated from chimpanzee in 1956, it
has been identified as an important cause of lower respiratory tract disease in infants …
has been identified as an important cause of lower respiratory tract disease in infants …
[HTML][HTML] Respiratory syncytial virus vaccines: a review of the candidates and the approved vaccines
X Topalidou, AM Kalergis, G Papazisis - Pathogens, 2023 - mdpi.com
Respiratory syncytial virus (RSV) is responsible for a significant proportion of global
morbidity and mortality affecting young children and older adults. In the aftermath of formalin …
morbidity and mortality affecting young children and older adults. In the aftermath of formalin …
Advances in respiratory syncytial virus vaccine development.
MC Kneyber, JL Kimpen - Current Opinion in Investigational Drugs …, 2004 - europepmc.org
Respiratory syncytial virus (RSV) is the most important causative agent of respiratory tract
infections. Young children with chronic lung or congenital heart disease are at increased risk …
infections. Young children with chronic lung or congenital heart disease are at increased risk …